---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-000984"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2023-07-14T23:59:59+00:00"
generated_at: "2026-06-13T08:18:25.389016+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Arcturus announces medRxiv preprint of Phase 3 data for ARCT-154 booster vs. Comirnaty

## Summary
- Preprint on medRxiv reports interim Phase 3 results from Japan comparing ARCT-154 booster to Comirnaty.
- Study conducted by Meiji Seika Pharma, Arcturus' collaborator, evaluating safety and immunogenicity.
- Meiji has a distribution agreement with CSL Seqirus for ARCT-154 in Japan, previously announced on April 11, 2023.
- The article is a preprint and has not yet been peer-reviewed; no specific results are provided in the filing.

## SEC filing metadata
- accession: 0001193805-23-000984
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2023-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000984/0001193805-23-000984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000984/e618777_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-000984
- JSON: https://secwatch.observer/filing/0001193805-23-000984.json
- Plain text: https://secwatch.observer/filing/0001193805-23-000984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.